



CORRECTION

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

Jean-David Fumet^{1,2,3,4}, Corentin Richard^{2,3,4}, Fanny Ledys^{2,3,4}, Quentin Klopfenstein^{2,3}, Philippe Joubert⁵, Bertrand Routy^{6,7}, Caroline Truntzer^{2,3}, Andréanne Gagné⁵, Marc-André Hamel⁵, Camila Figueiredo Guimaraes⁵, Bruno Coudert¹, Laurent Arnould⁸, Laure Favier¹, Aurélie Lagrange¹, Sylvain Ladoire^{1,4}, Pierre Saintigny⁹, Sandra Ortiz-Cuaran⁹, Maurice Perol⁹, Pascal Foucher¹⁰, Paul Hofman^{11,12}, Marius Ilie^{11,12}, Sandy Chevrier^{2,3}, Romain Boidot^{2,3}, Valentin Derangere^{2,3} and François Ghiringhelli^{1,2,3,4,13}

British Journal of Cancer (2019) 121:283; <https://doi.org/10.1038/s41416-019-0512-8>

Correction to: *British Journal of Cancer* (2018) **119**, 950–960; <https://doi.org/10.1038/s41416-018-0220-9>; published online 15 October 2018

Since the publication of this paper, the authors noticed that Corentin Richard was not credited as contributing equally to the paper. He should be considered as a joint first author with Jean-David Fumet.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹Department of Medical Oncology, Center GF Leclerc, Dijon, France; ²Research Platform in Biological Oncology, Dijon, France; ³GIMI Genetic and Immunology Medical Institute, Dijon, France; ⁴University of Burgundy-Franche Comté, Dijon, France; ⁵Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, QC, Canada; ⁶Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada; ⁷Hematology–Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada; ⁸Department of Pathology, Center GF Leclerc, Dijon, France; ⁹Department of Medical Oncology, Center Leon Berard, Lyon, France; ¹⁰Department of Thoracic Oncology, Dijon University Hospital, Dijon, France; ¹¹Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Nice University Hospital, Université Côte d'Azur, Nice, France; ¹²Hospital-Integrated Biobank (BB-0033-00025), FHU OncoAge, Nice University Hospital, Université Côte d'Azur, Nice, France and ¹³INSERM UMR1231, Dijon, France
Correspondence: François Ghiringhelli (fghiringhelli@cgfl.fr)

These authors contributed equally: Jean-David Fumet, Corentin Richard

Published online: 24 June 2019